MedWatch

Genmab's CEO pulls in DKK 37.3m salary – has shares worth DKK 1.6bn

Following an outstandingly profitable year for Genmab, CEO Jan van de Winkel got a pay raise, bringing his annual salary to DKK 37.3m. The CEO also owns a lucrative set of shares, which had a total market value of DKK 1.6bn at end-2020.

Genmab CEO Jan van de Winkel | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix

This year, money has once again rained down on Genmab's Dutch Chief Executive Officer Jan van de Winkel, after 2020 proved to be an outstandingly profitable fiscal year for the company. Its revenue succeeded the predicted DKK 10.1bn (USD 1.65bn).

For his efforts, the CEO received DKK 37.3m in 2020 against 35.2m in 2019, equivalent to a 6 percent pay raise.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs